Clinical Trial Search

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049

Primary: Number of Participants With Colds With at Least Moderate Intensity — 4; 2; 7; 0 Participants

Primary: Number of Participants With Rhinovirus-associated Illness Episodes — 63; 60 Participants

Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml

Primary: Virus Infection — 8; 18 Participants

Primary: Reduction in Viral Load in the URT — 3.6; 3.3; 4.9; 4.1 log 10 copies/mL — p=0.7146

Primary: Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) — 122.5; 137.1 hours — p=0.4009

Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml

Primary: Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection. — 4.0; 3.3 units on a scale — p=0.59

Primary: Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire — -9.12; -5.11 Scores on a scale — p=0.020

Primary: Number of Healthy and Asthmatic Participants With Events of Clinical Interest (ECI) (Part 1) — 1; 0; 0; 0 Participants

Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants

Primary: Total Lower Respiratory Symptom Score — 21; 18 score on a scale — p=0.78

Primary: Percentage of Participants With Rhinovirus PCR-Positive Colds — 2.6; 2.5 percentage of participants — p=0.973

Primary: The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses. — 47.1; 43.9 cold illnesses per 100 subjects — p=>0.5000

Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)

Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events

Primary: Sum of All Symptoms in Viruspositive Persons — 52; 52; 54; 56 units on a scale — p=<0.037

Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04

Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants

Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale

Primary: Change in Subjective Nasal Scoring — 0.62; 1.53 score on a scale — p=0.013

Primary: The Change From Baseline in the Mean of the 3 Single Symptom Scores (Blocked Nose, Sneezing and Running Nose) at the Closing/Final Visit. — -2 units on a scale

Primary: AUC (Area Under Curve) of Wisconsin Upper Respiratory Symptom Survey (WURSS-21) During First 8 Days of Symptoms as Compared Between Both Groups - Full Analysis Set (FAS)…

Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale

Primary: Number of Subjects With Required Adverse Events Grade II, III, and IV, Laboratory Adverse Events Grade II, III, and IV, and Severe Considered Adverse Events Related to…

Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants

Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants